Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 7/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epibatidine SCHEMBL316978 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL9070584 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL316977 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL29390446 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL5267259 | 0.98 | CHRNA7 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL6264689 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL5969577 | 0.98 | CHRNA7 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Homoepibatidine SCHEMBL29711361 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7663147 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL13596272 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-6255490-B1 | TREATING DISORDERS ASSOCIATED WITH CHANGES IN CHOLINERGIC ACTIVITY; NON-OPIATE BASED ANALGESIC FOR MODERATE TO SEVERE PAIN EQUALLY OR EXCEEDING THE POTENCY OF OPIATE ANALGESICS, YET LACKING ADDICTIVE SIDE EFFECTS | UNIVERSITY OF VIRGINIA | 2001-07-03 | — | — | US | disclosed |
| US-6117889-A | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents | UNIVERSITY OF VIRGINIA (US) | 2000-09-12 | — | — | US | disclosed |
| US-6060473-A | 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands | UCB S.A. - DTB (BE) | 2000-05-09 | — | — | US | disclosed |
| US-5969144-A | Radiolabeled pyridyl-7-azabicyclo[2,2,1]heptanes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0778835-A4 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIV VIRGINIA (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0778835-A1 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5565573-A | Synthesis of epibatidine and analogs thereof | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996006093-A1 | 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1994022868-A1 | 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885CHRNA7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.